Regulation of Downstream Targets: Volume 134 (Advances in Protein Chemistry and Structural Biology, 134). Questo articolo non è disponibile.Regulation of Downstream Targets: Volume 134 (Advances in Protein Chemistry and Structural Biology, 134)

Regulation of Downstream Targets, Volume 134 in the Advances in Protein Chemistry and Structural Biology series, presents interesting chapters on topics such as Transcriptional regulatory mechanisms and signaling networks in Viral Infections, Identification of potential key genes associated with pathogenesis and prognosis of endometrial cancer based on Integrated Bioinformatics Approaches, Differential regulation of genes in stage IB pancreatic cancer associated with increased risk of metastasis, AMPK-related LKB1-downstream targets, A compilation of bioinformatic approaches to identify novel downstream targets for the detection and prophylaxis of cancer, Protein phosphatases and their targets: Critical determinants of signaling pathway in plants, and more.

Other sections cover Calcium decoders and their targets: The holy alliance that regulate cellular responses, Importin alpha family NAAT/IBB domain: functions of a multi-faceted long chameleon sequence, Aurora Kinase A and related downstream molecules: A Potential Network for Cancer Therapy, Emerging Role of Heat Shock Proteins in Cardiovascular Diseases, Function, Structure, Evolution, Regulation and Drug Target Relevance of Arylalkylamine N-acetyltransferase, and Analysis of signaling cascades from myeloma cells treated with pristimerin.

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.